Showing posts with label Recommendations. Show all posts
Showing posts with label Recommendations. Show all posts

ACP Calls For Health Care Worker Immunizations

 

image

Photo Credit – CDC PHIL

# 5854

 

Today the American College of Physicians (ACP) – the second largest physician group in the United States – issued a statement supporting the immunization of all health care workers against influenza, along with a variety of other vaccine-preventable communicable diseases (including diphtheria; hepatitis B; measles, mumps, and rubella; pertussis (whooping cough); and varicella.

 

Their policy recommendations fall short of calling for across-the-board `mandatory’ vaccinations, as they do allow for exemptions due to medical reasons or religious objections to immunization.

 

You may recall that last October the  CMAJ (Canadian Medical Association Journal) endorsed requiring HCWs (Health Care Workers) to get a seasonal flu shot (see CMAJ On Mandatory Flu Shot For HCWs).

 

While strongly advocating influenza vaccination for HCPs, the CDC has stopped short of mandating them. I blogged on this back in June of 2010 (see CDC: Proposed Influenza Infection Control Guidance).

 

Many professional medical organizations have taken a stronger stance, adopting policies calling for mandatory vaccination of health care workers (HCWs).  A few earlier blogs on this include:

 

APIC Calls For Mandatory Flu Vaccination For HCWs
AAP: Recommends Mandatory Flu Vaccinations For HCWs
SHEA: Mandatory Vaccination Of Health Care Workers
IDSA Urges Mandatory Flu Vaccinations For Healthcare Workers

 

This latest call for flu vaccination comes as the first state-mandated flu vaccine requirement for HCWs – see Rhode Island Adopts New Flu Vaccination Requirements For HCPs - is being contested by a healthcare worker’s union in court. 

 

This from AMEDNEWS.COM.

 

First state flu shot mandate at center of legal battle

A union is suing Rhode Island over a regulation requiring all health workers to receive influenza vaccine or wear masks while they’re working.

By Alicia Gallegos, amednews staff. Posted Jan. 14, 2013.

The Rhode Island Dept. of Health is asking a federal judge to throw out a lawsuit challenging its recently issued mandate that health care employees receive the influenza vaccine.

(Continue . . . )

 

While many infection control experts see mandatory immunization a necessary and long overdue step in patient and co-worker protection, this is a hugely divisive issue, with many HCWs believing that it is an infringement of their rights to decide what will be injected into their bodies.

 

I’ve covered HCW’s objections to forced flu shots in the past, including:

 

HCWs: Refusing To Bare Arms

HCWs: Developing a Different Kind Of Resistance

 

Despite recent studies showing that flu shots provide only about 60% protection against influenza, many hospitals see this as both a liability and an economic issue, on top of their concerns over patient welfare.

 

Which is why – despite protests from some employees – an increasing number of hospitals and medical offices are making flu vaccination mandatory over the past few years. A couple of recent examples include:

 

Mandatory Flu Shots For Children's Medical Center Employees

Hospital's 'Cocoon Strategy' Aimed At Protecting Young Patients

 

Local health system mandates flu vaccine for upcoming season

 

 

 

Here is the ACP link, and some excerpts, from today’s press release:

 

American College of Physicians calls for immunizations for all health care providers

40,000 to 50,000 adults die from vaccine-preventable diseases each year in the U.S.

PHILADELPHIA, January 14, 2013 -- The American College of Physicians (ACP) has approved a policy recommendation that all health care providers (HCPs) be immunized against influenza; diphtheria; hepatitis B; measles, mumps, and rubella; pertussis (whooping cough); and varicella (chickenpox) according to the Advisory Committee on Immunization Practices (ACIP) Adult Immunization Schedule. ACP’s policy exempts HCPs for medical reasons or a religious objection to immunization.

 

“These transmissible infectious diseases represent a threat to health care providers and the patients we serve, who are often highly vulnerable to infection,” said David L. Bronson, MD, FACP, president, ACP. “Proper immunization safely and effectively prevents a significant number of infections, hospitalizations, and deaths among patients as well as preventing workplace disruption and medical errors by absent workers due to illness.”

 

With a severe flu season underway, ACP urges all adults to get a flu shot if they haven’t already and to talk with their internist about other immunizations they might need. Only 39 percent of adults received the flu vaccine during the 2011-12 season. People who cannot get a flu shot or other immunizations for medical reasons should talk to their internist about other ways of protecting themselves.

 

ACP is committed to improving public health through encouraging appropriate immunization of adults. In August 2012, ACP was awarded an initial $175,000 of a total $525,000 grant for 2012-13 from the Centers for Disease Control and Prevention (CDC) to create a three-year, evidence-based program to increase adult immunization rates in five states. In addition, the American Board of Internal Medicine (ABIM) approved practice improvement credit for the Medical Home Builder adult immunization module for recertifying physicians.

 

(Continue . . . )

Popular among HCWs or not  – short of an overturn in the courts – the requirement for annual flu vaccinations in HCPs continues to gain traction across the country, and around the world.

 

»» Read More

WHO: Northern Hemisphere 2012-2013 Flu Vaccine Composition

 

image

Photo Credit PHIL

# 6167

 

 

After consultations this week with public health officials, researchers, and pharmaceutical companies the World Health Organization has released their recommendation for the antigen composition of this fall’s trivalent flu vaccine.

 

 

Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season

It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:

  • an A/California/7/2009 (H1N1)pdm09-like virus;
  • an A/Victoria/361/2011 (H3N2)-like virus;
  • a B/Wisconsin/1/2010-like virus.
For more information
                                   

                                        Due to the continual antigenic drift of flu viruses, flu vaccine formulations are frequently adjusted. After 3 years with essentially no changes in the flu vaccine, this new formulation makes changes to both the H3N2 and B virus strains.

                                         

                                        The H1N1 component remains essentially unchanged, with the A/California/7/2009 (H1N1)pdm09-like  still recommended.

                                         

                                        • The old A/Perth/16/2009 (H3N2)-like virus now gives way to the A/Victoria/361/2011 (H3N2)-like virus.
                                        • And the Victoria lineage B/Brisbane/60/2008-like virus will be replaced by a Yamagata strain; the B/Wisconsin/1/2010-like virus. 

                                         

                                        While the World Health Organization makes vaccine recommendations twice each year (Recommendations  are made in September for the Southern Hemisphere), national and regional public health organizations are responsible for deciding what formulation to use locally.

                                        »» Read More

                                        ACIP Broadens Adult Immunization Recommendations

                                         

                                        image

                                        Photo Credit PHIL

                                        # 6113

                                         

                                         

                                        ACIP, the CDC's Advisory Committee on Immunization Practices, has published their revised recommendations for adult immunizations today in the February 1st edition of the Annals of Internal Medicine.

                                         

                                        Among the changes, ACIP now recommends routine HPV vaccination for males aged 11 to 12 years, and has broadened their recommendations for administering the Hepatitis B vaccine.

                                         

                                        The entire recommendation can be read at:

                                         

                                        Recommended Adult Immunization Schedule: United States, 2012*

                                        1. Advisory Committee on Immunization Practices†

                                         

                                        But for the short version, we have this press release from the American College of Physicians.

                                         

                                        2012 adult immunization schedule broadens recommendations for HPV and hepatitis B vaccinations

                                        Annals of Internal Medicine early release article for Feb. 1, 2012

                                        Philadelphia, February 1, 2012 – The CDC's Advisory Committee on Immunization Practices (ACIP) now recommends routine HPV vaccination for males aged 11 to 12 years and catch-up vaccination for males aged 13 to 21. These are just two of the changes to the 2012 Recommended Adult Immunization Schedule being published February 1 in Annals of Internal Medicine (www.annals.org), the flagship journal of the American College of Physicians (ACP).

                                         

                                        In addition to the changes in the HPV vaccine, the ACIP now recommends vaccination against Hepatitis B for adults younger than age 60 who have diabetes, as soon as possible after diabetes is diagnosed. Hepatitis B vaccinations should also be given to adults with diabetes aged 60 years or older based on a patient's need for assisted blood glucose monitoring, likelihood of acquiring hepatitis B, and likelihood of immune response to vaccination.

                                         

                                        The ACIP is comprised of the ACP and 16 other medical societies representing various medical practice areas. Each year, the ACIP reviews the CDC's Recommended Adult Immunization Schedule to ensure the schedule reflects current clinical recommendations for licensed vaccines. The recommendations are intended to guide physicians and other clinicians about the appropriate vaccines for their adult patients. In October 2010, the ACIP adopted an evidence-based process that considers quality of evidence, benefits and harms, values and preferences of affected populations, and economic impact. Voting to expand routine HPV vaccination to males and hepatitis B vaccinations to young adult diabetics was the first exercise of this approach.

                                         

                                        Changes were also made to when mothers should receive the tetanus, diphtheria, and acellular pertussis (Tdap) booster that is designed to protect infants from pertusiss. According to the 2012 schedule, women should receive the vaccine during pregnancy, preferably after 20 weeks of gestation. Protective maternal antibodies will pass to the fetus.

                                         

                                        Adult patients should continue to be vaccinated against influenza. Egg allergy is no longer a contraindication, but patients with an egg allergy should get the inactivated flu shot because that is what has been studied.

                                         

                                        A footnote was added to the schedule directing readers to links for the full ACIP vaccine recommendations. Specific vaccine recommendations for travelers also were added. In another new addition, the schedule now includes a table summarizing precautions and contraindications for vaccines.

                                        ###

                                        The full 2012 Recommended Adult Immunization Schedule can be viewed at www.annals.org.

                                        »» Read More

                                        WHO: Southern Hemisphere 2012 Flu Vaccine Composition

                                         

                                        image

                                         

                                        #5876

                                         

                                         

                                        Twice each year influenza experts gather to discuss recent developments in human and animal influenza viruses around the world, and to decide on the composition of the next influenza season’s flu vaccine.

                                         

                                        Due to the time it takes to manufacture a vaccine, decisions on which strains to include must be made six months in advance. 

                                         

                                        The composition of the northern hemisphere’s vaccine is decided upon in February of each year, and decisions on the southern hemisphere’ vaccine are made in September.

                                         

                                        Accordingly, last week representatives from divisions of the World Health Organization’s  GISRS (Global Influenza Surveillance and Response System), along with members of OFFLU (the OIE/FAO Network on Animal Influenza), and other experts gathered in Chavannes-de-Bogis, Switzerland.

                                         

                                        The agenda for this meeting (WHO Consultation on the Composition of Influenza Vaccine for the Southern Hemisphere 2012) states the following objectives:

                                         

                                        1.  Analyse the antigenic and genetic characteristics of influenza viruses circulating and infecting humans, taking into consideration of available epidemiological and clinical information from individual countries and regions;

                                         
                                        2.  Make recommendations on the composition of the influenza vaccines for use in the southern hemisphere 2012;


                                        3.  Review the antigenic and genetic characteristics of recent A(H5N1) viruses that the WHO Collaborating Centres of the WHO GISRS received and the need to develop new A(H5N1) candidate vaccine viruses for pandemic preparedness purposes; 


                                        4.  Review the antigenic and genetic characteristics of other subtype influenza viruses, if any, infecting humans recently, and the need to develop new candidate vaccine viruses for pandemic preparedness purposes. 

                                         

                                        Below are some excerpts from their 15-page report: Recommended composition of influenza virus vaccines for use in the 2012 influenza season - full report

                                         

                                         

                                        Zoonotic influenza infections caused by avian A(H5N1), avian A(H9N2) and swine A(H3N2) viruses

                                        From 16 February 2011 to 19 September 2011, 45 confirmed human cases of A(H5N1), 24 of which were fatal, were reported by Bangladesh, Cambodia, Egypt and Indonesia, countries in which highly pathogenic avian influenza A(H5N1) is present in poultry. Since December 2003, a total of 564 cases with 330 deaths have been confirmed in 15 countries. To date there has been no evidence of sustained human-to-human transmission.


                                        One human case of influenza A(H9N2) was detected in Bangladesh and four human infections caused by swine A(H3N2) viruses were detected in the United States of America during the same period. 

                                         

                                        Under the heading: Antigenic and genetic characteristics of recent isolates, the group found that despite growing diversity among variants of the 2009 H1N1 pandemic virus, the vast majority remain antigenically similar to the original virus.

                                         

                                         

                                        Influenza A(H1N1) viruses

                                        Between February and August 2011, all influenza A(H1N1) viruses detected worldwide were A(H1N1)pdm09; no former seasonal A(H1N1) viruses were detected. Haemagglutination inhibition (HI) tests using post-infection ferret antisera indicated that A(H1N1)pdm09 viruses remained antigenically homogeneous and closely related to the vaccine virus A/California/7/2009.

                                         

                                        The same could be said for the H3N2 virus, where the majority of samples remain antigenically similar to the A/Perth/16/2009 virus which has been part of the flu vaccine for the past couple of years.

                                         

                                        Influenza A(H3N2) viruses

                                         

                                        The majority of A(H3N2) viruses collected  from February to August 2011 were antigenically closely related to the vaccine virus A/Perth/16/2009. Antigenic characteristics were assessed with panels of post-infection ferret antisera in HI and virus neutralization assays. The HA genes of recent viruses fell into two phylogenetic clades represented by A/Perth/16/2009 and A/Victoria/208/2009, with the  vast  majority falling within the A/Victoria/208/2009 clade.

                                         

                                        Influenza B is always a bit of a wildcard, since there are two main strains in circulation, and only one is currently included in the vaccine. In recent years the Victoria strain has been dominant, but the Yamagata lineage waits in the wings and continues to circulate in northern China.

                                         


                                        Influenza B viruses


                                        Influenza B viruses  of both the B/Victoria/2/87 and the B/Yamagata/16/88 lineages  co-circulated, with B/Victoria/2/87 lineage viruses continuing to predominate globally. However,in  northern  China, B/Yamagata/16/88 lineage viruses predominated from  February  to  May 2011 before influenza activity declined. 

                                         

                                         

                                        The bottom line: The bulk of the influenza viruses currently circulating, while they continue to evolve, remain antigenically similar to to those that have been including in the flu vaccine since 2010.

                                         

                                        When a strain is said to be `antigenically similar’  to the vaccine strain, it is expected (but not assured) that the vaccine remains reasonably effective. 

                                         

                                        While research and refinements in candidate vaccines continue, next year’s vaccine recommendations for the southern hemisphere remains essentially the same for the third year in a row. 

                                         

                                        The report concludes:

                                         

                                        It is expected that  A(H1N1)pdm09, A(H3N2) and B viruses will co-circulate in the 2012 southern hemisphere season.

                                         

                                        It is recommended that the following viruses be used for influenza vaccines in the 2012 influenza season (southern hemisphere):


                                        – an A/California/7/2009 (H1N1)pdm09-like virus;
                                        – an A/Perth/16/2009 (H3N2)-like virus;
                                        – a B/Brisbane/60/2008-like virus. 

                                         

                                         

                                        Flu viruses are constantly changing, mutating, and evolving making any forecast a bit of a gamble. As we saw with the 2009 H1N1 swine flu, a novel virus can emerge and change the viral landscape practically overnight.

                                         

                                        But despite the variability  and unpredictability of influenza, the track record for selecting influenza A strains for the flu shot has actually been pretty good over the years.

                                         

                                        We won’t know how well this decision will turn out in the southern hemisphere for another 6 to 12 months, but for those of us north of the equator, this is a pretty good indication that confidence in the makeup of this fall’s flu vaccine remains high.

                                         

                                        A good enough reason to go ahead and get the shot this year, before flu season arrives.

                                        »» Read More

                                        WHO: Northern Hemisphere 2011-2012 Flu Vaccine Composition

                                         

                                         

                                        # 5321

                                         

                                         

                                        After consultations this week with public health officials, researchers, and pharmaceutical companies the World Health Organization has released their recommendation for the antigen composition of this fall’s trivalent flu vaccine.

                                         

                                         

                                        Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season

                                        It is recommended that vaccines for use in the 2011-2012 influenza season (northern hemisphere) contain the following:

                                        • an A/California/7/2009 (H1N1)-like virus;
                                        • an A/Perth/16/2009 (H3N2)-like virus;
                                        • a B/Brisbane/60/2008-like virus.

                                         

                                        If this list looks familiar, it’s because this is the same mixture the WHO recommended for last fall’s flu shot, and the one to be used over the coming months in the southern hemisphere.

                                         

                                        The WHO also posted a full report with their rationale for each strain selection which you can access at:

                                         

                                        Recommended composition of influenza virus vaccines for use in the 2011-2012 influenza season - full report.

                                         

                                         

                                        The short version is: while minor variations have been observed in both the 2009 H1N1 and the seasonal H3N2 viruses over the past year, HI (Hemagglutination inhibition) testing of isolates suggest that the vast majority remain antigenically indistinguishable from the recommended strains.

                                         

                                        Lisa Schnirring, writing for CIDRAP, has a nice summation of today’s report, along with information about new H5N1 vaccine candidates.

                                         

                                        WHO sticks with current strains for next flu vaccine

                                        Lisa Schnirring * Staff Writer

                                        Feb 17, 2011 (CIDRAP News) – Signaling that the current flu strains are likely to persist over the next several months, the World Health Organization (WHO) today recommended sticking with the current trio of vaccine strains for the Northern Hemisphere's next influenza season.

                                        (Continue . . .)

                                        »» Read More

                                        ACCV Teleconference Today

                                         

                                         


                                        # 4767

                                         

                                         

                                        With the fall flu vaccination campaign slated to begin less than 2 months from now, the ACCV (Advisory Commission on Childhood Vaccines) will hold a teleconference this afternoon to review the CDC's draft statements for the upcoming flu season.

                                         

                                        Interested parties may listen in, or make a public comment at the end of the meeting. 

                                         

                                        This notice appears on the right hand news column of the HRSA Vaccine Compensation Website.

                                         

                                         

                                        Interim Influenza Vaccine Information Statements Special Meeting

                                        Thursday July 29, 1 to 2 pm ET

                                        The Advisory Commission on Childhood Vaccines will review the CDC's draft statements slated for distribution during the 2010-2011 flu season. The conference call meeting is open to the public. Persons who wish to make oral statements may announce their intent at the time of the public comment period.


                                        To join, phone 1-888-606-5950.
                                        Leader’s Name: Dr. Geoffrey Evans
                                        Password: ACCV

                                        Meeting Agenda (PDF - 10 KB)

                                        Federal Register (PDF - 57 KB)

                                        Inactivated Influenza Vaccine: What You Need to Know 2010 – 2011 (PDF - 33 KB)

                                        Live, Intranasal Influenza Vaccine: What You Need to Know 2010 – 2011 (PDF - 36 KB)

                                        VICP Authorizing Legislation (PDF - 497 KB) (January 13, 2010)

                                        Review of Adverse Effects of Vaccines Committee Membership Comment on provisional appointments by April 9

                                        »» Read More

                                        ACIP Adjusts Pediatric Flu Vaccine Recommendations

                                         

                                         

                                        # 4674

                                         

                                         

                                        Yesterday ACIP  (the CDC’s Advisory Committee on Immunization Practices) made a small adjustment to this fall’s seasonal flu vaccine recommendations for children under the age of 10.

                                         

                                        In a non-unanimous decision (10-5), the panel voted that children who didn’t receive at least one dose of the H1N1 pandemic vaccine last year should receive two doses of the trivalent seasonal vaccine this year.

                                         

                                        Those that already received the monovalent H1N1 vaccine would only need one shot. 

                                         

                                        Lisa Schnirring of CIDRAP has the details, along with some information on studies being conducted by the CDC  on CSL’s trivalent vaccine which produced an unusually high number of side effects (mostly fever) in Australian children under the age of five.

                                         

                                        CDC advisors tweak seasonal flu vaccine advice for young kids

                                        Lisa Schnirring * Staff Writer

                                        Jun 24, 2010 (CIDRAP News) – Aiming to close some of the gaps in protection against the pandemic H1N1 virus expected to circulate this fall, a federal vaccine advisory group today recommended that children aged 6 months to 9 years who haven't received at least one dose of monovalent pandemic vaccine receive two doses of the upcoming season's trivalent vaccine.

                                         

                                        The Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) made the recommendation at its meeting today after seeing the most recent immunogenicity data for the pandemic vaccine. Though it was 62% protective among all age-groups after one dose, rates were lower in younger children. Some CDC experts said this supports the recommendation for a 2-dose, prime-boost pandemic immunization strategy for children 6 months to 9 years old.

                                        (Continue . . .)

                                        »» Read More

                                        ACIP Provisional Influenza Vaccine Recommendations

                                         

                                         

                                        # 4400

                                         

                                        Before you skip past what sounds like it will be a boring and routine report . . . read on. 

                                         

                                        There’s some news to be had here.

                                         

                                        Aside from recommending nearly universal flu vaccinations (just about everyone over the age of 6 mos.), ACIP (Advisory Committee on Immunization Practices) has announced the availability of a high dose flu vaccine for the 2010-11 season for those over the age of 65.

                                         

                                        One of the concerns about the flu vaccine has been the less robust immune response in those (traditionally) most at risk from influenza – the elderly.

                                         

                                        While a healthy adult under the age of 65 may see a 70%-90% level of protection from a well-matched flu vaccine, those over the age of 65 often see far less.   

                                        A few choice blogs on this topic include:

                                         

                                        Another Study: Flu Vaccines Do Not Reduce Mortality Rates In The Elderly

                                         

                                        Study: Flu Vaccines And The Elderly

                                         

                                        Flu Shots For The Elderly May Have Limited Benefits

                                         

                                        Roughly 18 months ago we learned (see Vaccines: Sometimes You Just Need A Bigger Hammer) of a study conducted by Sanofi-Pasteur where several thousand people over the age of 65 were given a flu vaccine with 4 times the antigen of a standard shot.  

                                         

                                        Instead of 15ug of antigen per strain, these shots contained 60ug.

                                         

                                        Those who received the stronger shot developed a significantly stronger immune response than those who received the standard dose.

                                         

                                        The FDA approved the use of Sanofi’s High Dose Fluzone last December.

                                         

                                         

                                        FDA PRESS RELEASE

                                        For Immediate Release: Dec. 23, 2009

                                        FDA Approves A High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older

                                        Accelerated approval process used in vaccine approval

                                        The U.S. Food and Drug Administration today approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B.

                                        People in this age group are at highest risk for seasonal influenza complications, which may result in hospitalization and death. Annual vaccination remains the best protection from influenza, particularly for people 65 and older.

                                        (Continue . . . )

                                         

                                        ACIP has not expressed a preference for the new High Dose Fluzone for those over 65, so eligible recipients should discuss that option with their personal physician.

                                         

                                        It will likely take a year or more before scientists can assess the impact of this higher dose flu vaccine. 

                                         

                                        Here then are the Provisional recommendations for the upcoming flu season, released yesterday. 

                                         

                                         

                                        ACIP Provisional Recommendations for the Use of Influenza Vaccines

                                        Date of ACIP vote: February 24, 2010 Date of posting of provisional recommendations: March 2, 2010


                                        Tentative date of publication of recommendations in CDC Morbidity and Mortality Weekly Report: June 2010


                                        On February 24, 2010, the ACIP voted on updated recommendations for use of trivalent seasonal influenza vaccine for the 2010-2011 influenza season.


                                        Provisional recommendations for the prevention and control of seasonal influenza (2010-2011 influenza season):


                                        Vaccination recommendations for adults were expanded to include all adults beginning in the 2010-11 influenza season.

                                        Therefore, all people age 6 months and older are now recommended to receive annual influenza vaccination.


                                        Background information on influenza vaccines

                                        •The 2010–2011 trivalent vaccines will contain A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens. Compared to the 2009-10 Northern Hemisphere influenza vaccine, the influenza A(H1N1) and A(H3N2) strains are changed. The A/California/7/2009 (H1N1)-like strain is the same strain that was included in the pandemic influenza A(H1N1) 2009 monovalent vaccines.


                                        •A higher dose formulation of an inactivated seasonal influenza vaccine (Fluzone High-Dose, manufactured by sanofi pasteur, licensed by FDA on December 23, 2009) for use in people age 65 years and older will be available in the 2010-11 influenza season.∗ Fluzone High-Dose contains four times the amount of influenza antigen compared to other inactivated seasonal influenza vaccines. Fluzone High-Dose vaccine in one study of people age 65 years and older produced higher antibody levels, but slightly higher frequency of local reactions. Studies are underway to assess the relative effectiveness of Fluzone High-Dose compared to standard dose inactivated influenza vaccine, but results from those studies will not be available before the 2010-11 influenza season. The ACIP has not expressed a preference for Fluzone High-Dose or any other licensed inactivated influenza vaccine for use in people age 65 and older.


                                        •An additional inactivated vaccine (Agriflu, manufactured by Novartis, licensed by FDA on November 27, 2009) will be available in the 2010-11 influenza season.† Agriflu is licensed for use in people age 18 years and older.


                                        •Age indications for two inactivated influenza vaccines have changed. Afluria, manufactured by CSL Vaccines, is now licensed for use in people age 6 months and older. Fluarix, manufactured by GSK Biologicals, is now licensed for use in people age 3 years and older.


                                        ∗ Fluzone High-Dose has been licensed by FDA, but will not be available until the 2010-11 influenza season.
                                        † Agriflu has been licensed by FDA, but will not be available until the 2010-11 influenza season.

                                        »» Read More

                                        ACIP Recommends Near `Universal’ Flu Vaccinations

                                         

                                         

                                        # 4384

                                         

                                         

                                        ACIP, the Advisory Committee on Immunization Practices, yesterday came forth with a long anticipated recommendation that just about all Americans over the age of 6 months should receive a yearly flu vaccination.

                                         

                                         

                                        Maggie Fox, science and health editor for Reuters, brings us the details in her story.

                                         

                                        UPDATE 1-Everyone in US should get flu vaccine - experts

                                        Thu Feb 25, 2010 1:44am GMT

                                        (Updates with vote on flu vaccine)

                                        * 97 million H1N1 vaccines administered in U.S.

                                        * Deaths could exceed normal seasonal flu year

                                        * Obese and children at highest risk

                                        By Maggie Fox, Health and Science Editor

                                        WASHINGTON, Feb 24 (Reuters) - Everyone in the United States over the age of six months should get seasonal influenza vaccines every year, federal vaccine advisers said on Wednesday.

                                         

                                        The Advisory Committee on Immunization Practices made the long-awaited vote to recommend virtually universal flu vaccination -- something public health experts have long recommended.

                                         

                                        "The new recommendation seeks to remove barriers to influenza immunization and signals the importance of preventing influenza across the entire population," the U.S. Centers for Disease Control and Prevention said in a statement.

                                         

                                        Earlier, experts told the committee that people who were morbidly obese and school-aged children were much more likely to become seriously ill or to die from H1N1 swine flu, as opposed to seasonal flu, which mostly kills the frail elderly.

                                        (Continue . . .)

                                         

                                         

                                        Two additional points are  brought out in this article.

                                         

                                        First, Maggie reports that H3N2 is on the rise in China, accounting now for about 6% of their influenza cases.  This suggests that reports of seasonal flu’s demise may yet be premature.

                                         

                                        Second is that the pandemic death toll in the United States – now estimated at near 17,000 – may be revised upward over the coming months and may exceed the 36,000 deaths we `expect’ from an average flu season.

                                         

                                        (36K deaths is the CDC’s yearly estimate of flu deaths.  Not a count)

                                         

                                        While many have been quick to latch onto early numbers and jump to conclusions regarding the impact and severity of this pandemic, the simple truth is that it will take months – likely years – before we can analyze most of the data.

                                         

                                        Until then, pronouncements regarding this pandemic need to be viewed as preliminary at best.

                                        »» Read More